Need Help?

Evaluation of commercial Guardant360 ctDNA test in metastatic prostate cancer

Circulating tumor DNA (ctDNA) sequencing provides a minimally-invasive method for tumor molecular stratification. We compared the commercial Guardant360 ctDNA test to an academic sequencing approach for profiling of metastatic prostate cancer. Plasma cell-free DNA (cfDNA) from 24 patients was sequenced with a validated, prostate cancer specific targeted research panel, and sent for simultaneous Guardant360 analysis.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001004486 Illumina HiSeq 2500 48
Publications Citations
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer.
JCO Precis Oncol 3: 2019 PO.19.00014